Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

402 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, Mestan J, O'Reilly T, Traxler P, Chaudhuri B, Fretz H, Zimmermann J, Meyer T, Caravatti G, Furet P, Manley PW. Fabbro D, et al. Pharmacol Ther. 2002 Feb-Mar;93(2-3):79-98. doi: 10.1016/s0163-7258(02)00179-1. Pharmacol Ther. 2002. PMID: 12191602 Review.
In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase.
García-Echeverría C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, Gao J, Brueggen J, Capraro HG, Cozens R, Evans DB, Fabbro D, Furet P, Porta DG, Liebetanz J, Martiny-Baron G, Ruetz S, Hofmann F. García-Echeverría C, et al. Among authors: fabbro d. Cancer Cell. 2004 Mar;5(3):231-9. doi: 10.1016/s1535-6108(04)00051-0. Cancer Cell. 2004. PMID: 15050915 Free article.
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G. Traxler P, et al. Among authors: fabbro d. Cancer Res. 2004 Jul 15;64(14):4931-41. doi: 10.1158/0008-5472.CAN-03-3681. Cancer Res. 2004. PMID: 15256466
Imatinib: a selective tyrosine kinase inhibitor.
Manley PW, Cowan-Jacob SW, Buchdunger E, Fabbro D, Fendrich G, Furet P, Meyer T, Zimmermann J. Manley PW, et al. Among authors: fabbro d. Eur J Cancer. 2002 Sep;38 Suppl 5:S19-27. doi: 10.1016/s0959-8049(02)80599-8. Eur J Cancer. 2002. PMID: 12528769 Review.
A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity.
Meyer T, Regenass U, Fabbro D, Alteri E, Rösel J, Müller M, Caravatti G, Matter A. Meyer T, et al. Among authors: fabbro d. Int J Cancer. 1989 May 15;43(5):851-6. doi: 10.1002/ijc.2910430519. Int J Cancer. 1989. Retraction in: Int J Cancer. 1999 May 17;81(4):669. doi: 10.1002/(sici)1097-0215(19990517)81:4<669::aid-ijc26>3.0.co;2-f PMID: 2714889 Retracted.
402 results